US Stock MarketDetailed Quotes

TGTX TG Therapeutics

Watchlist
  • 34.800
  • -0.200-0.57%
Close Nov 29 13:00 ET
  • 34.810
  • +0.010+0.03%
Post 16:36 ET
5.42BMarket Cap-348000P/E (TTM)

TG Therapeutics Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

TG Therapeutics Q3 2024 Earnings Date

Currency：USDNov 4, 2024

Estimate
(YoY)		 Actual
(YoY)		 Vs Estimate
(% Chg)
Revenue
81.70M
83.88M
+2.17M
Beat Est.
-50.73%
-49.41%
+2.66%
EPS
0.03
0.02
-<0.01
Miss Est.
-96.22%
-97.26%
-27.54%
Analyst Rating
Strong Buy

Nov 30, 2024

TG Therapeutics Earnings Estimates

Revenue

EPS

EBIT

Revenue is based on 4 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement

Currency: USD

Actual
Estimate
DatePeriodRevenue/EstimateEarnings Call
--2025/Q1-- / 110.839M--
--2024/Q4-- / 98.424M--
Nov 4, 20242024/Q383.879M / 81.705M--
Aug 6, 20242024/Q273.466M / 65.893M--
May 1, 20242024/Q163.474M / 54.608M--
DatePeriodRevenue/EstimateEarnings Call
--2025/Q1-- / 110.839M--
--2024/Q4-- / 98.424M--
Nov 4, 20242024/Q383.879M / 81.705M--
Aug 6, 20242024/Q273.466M / 65.893M--
May 1, 20242024/Q163.474M / 54.608M--

Unlock Free Earnings Estimates

TG Therapeutics Earnings Reports

  • TG Therapeutics | 10-Q: Q3 2024 Earnings Report

    Nov 7 16:38 ET

  • TG Therapeutics | 8-K: ® TG Therapeutics Reports Third Quarter 2024 Financial Results and Raises BRIUMVI (ublituximab-xiiy) Full Year Revenue Guidance

    Nov 4 07:24 ET

  • TG Therapeutics | 10-Q: Q2 2024 Earnings Report

    Aug 9 16:12 ET

  • TG Therapeutics | 10-K/A: Annual report (Amendment)

    Aug 9 16:03 ET

    • Read more

    Analysis

    Analyst Rating

    Updated: Nov 30, 2024

    Strong Buy

    • Buy

      100.00%

    • Hold

      0.00%

    • Sell

      0.00%

    Price Target

    No Data

    Heat List
    US
    Overall
    Symbol
    Latest Price
    % Chg

    No Data